Heart Failure: Mending a Broken Heart

Shalon R. Buchs, MHS, PA-C

Objectives:

2

1. Discuss heart failure in terms of etiology, diagnosis and management.

- 2. Outline the primary differences between acute and chronic heart failure in terms of symptoms and management.
- 3. Compare and contrast systolic and diastolic heart failure. (Heart failure with preserved ejection fraction (HFpEF) and Heart failure with reduced ejection fraction (HFrEF)).
- 4. Outline the New York Heart Association (NYHA) classification of CHF
 5. Create treatment plans for patients with each type of heart failure
 6. Recognize signs of poor prognosis in patients with heart failure

Epidemiology & Burden of disease

Incidence and prevalence of HF increases with age.

- There are an estimated 6 million people with HF in the US.
- In 2014, there were 1,068,412 ED visits; 978,135 hospitalizations and 83,705 deaths attributed to primary HF.
 - The numbers for comorbid HF in the same year were at least tripled.
- Average hospitalization for a primary HF patient in 2014 was ~\$11,552



What is Heart Failure?

Complex clinical syndrome resulting from structural or functional impairment of the ventricle meeting the metabolic demand of the body.

Bottom line: either filling of, or ejection from the ventricle is not sufficient to meet the needs of the body.



Coronary heart disease
Cigarette smoking
Hypertension

Obesity
 Diabetes
 Valvular Heart disease

If HF is anything that prevents the heart from pumping enough blood to meet body's metabolic demand...What are the causes?



6

If HF is anything that prevents the heart from pumping enough blood to meet body's metabolic demand...

Heart Muscle

Valve

Electrical – Rhythm Myocardial infarction, Hypertrophy, Muscle damage from – Virus, drug, infiltrating (inflammatory) disease, genetic defect



- What valve problems block blood from getting to the aorta or overwhelm the ventricle... more on this later
- Too slow not enough outflow
- Too fast- not enough filling time or uncoordinated, chaotic ventricle is ineffective

HF – Major Categories

Left Sided

8

- Signs and Symptoms of Left Heart Failure
- Symptoms
 - Dyspnea
 - Orthopnea
 - PND
 - Fatigue
 - MS Changes
 - Cough
 - Weight gain

- Signs
 - Tachycardia
 - Tachypnea
 - Gallop (S3 or S4)
 - Crackles, Pulmonary edema
 - JVD **
 - Edema **
 - Hepatojugular reflux **
 - Jaundice **

- Why does this happen?
 - Left ventricle is backing up into left atrium and ultimately into the lungs
- What are the causes?
 - There are many causes anything that stresses the left ventricle
 - #1 cause is coronary ischemia/ myocardial infarction

** Late or Advanced Finding

Reduced Ejection Fraction Heart Failure

- ► Heart failure with reduced ejection fraction (HFrEF) (formerly systolic dysfunction) → characterized by a left ventricular ejection fraction of ≤40%, often with increased LV volume
 - Coronary heart disease
 - Idiopathic dilated cardiomyopathy
 - HTN
 - Valvular disease

HF – Major Categories

Reduced (HFrEF)

- With a dilated LV the atrium fills the ventricle just fine
- Ventricle is weak so can't eject enough blood to meet metabolic needs

Pumping problem

- Example if EDV is high at 150 ml
 - ► EF = 30% = SV/150
 - SV = 45 ml of blood ejected per beat
 - Not enough to meet demand



Preserved Ejection Fraction Heart Failure

- Heart failure with preserved ejection fraction (HFpEF) (formerly diastolic dysfunction) → characterized by a left ventricular ejection fraction of ≥50%, may have normal LV volume.
- Pt. with an EF between 41-49% may be considered HFpEF borderline and have characteristics similar to patients with HFpEF.

HTN

- Coronary heart disease
- Restrictive cardiomyopathy
- Hypertrophic obstructive cardiomyopathy

HF – Major Categories

- Preserved (HFpEF)
- How can you have heart failure w/ normal EF?
- Normal Stroke Volume ~ 70ml
 - Beginning of Systole Left Ventricle (LV) =120ml also called End-Diastolic Volume (EDV)
 - End of Systole LV has ~ 50ml
 - EF = Stroke volume / EDV
 - EF = 70 ml / 120 ml = **58% (Normal EF)**

With a hypertrophied LV, the thin atrium can't push enough blood into thick, strong ventricle so EDV is not 120ml its lower. Filling problem.

- Example if EDV = 80 ml
- ► EF = 58% = SV/80

SV = 47ml of blood ejected per beat - Not enough to meet demand w/ activity

_ не

12



HF – Major Categories

Preserved (HFpEF)



Commonly Hypertrophic: Thick, stiff, Strong Heart Usually symmetrical – R and L same time

Reduced (HFrEF)



Commonly Dilated: Large, Weak Heart Often Left affected first then Right Ventricle

Signs and symptoms

 Dyspnea
 Orthopnea, PND
 Fatigue
 Exercise intolerance

S3, S4
Palpitations
Cough
Edema
JVD



HF – Major Categories - Causes

Preserved (HFpEF)

- Causes: Things resulting in stiff heart muscle (usually on R & L same time)
 - Hypertension (HTN) \rightarrow hypertrophy
 - Diabetes (DM)– 2-4 X incidence of CHF even w/o CAD or HTN
 - DM causes fibrosis muscle & nerve damage leads to stiffness
 - Other diseases that infiltrate or stiffen muscle
 - Muscular dystrophy, Amyloidosis, Connective tissue diseases

Commonly Hypertrophic: Thick, Strong, Heart

Reduced (HFrEF)

- Causes: Things that weaken the ventricle (usually Left)
 - Coronary Artery Disease- MI #1 by far
 - HTN, DM, smoking, obesity increase risk
 - Valve disease
 - Peri-partum
 - HIV or other virus
 - Arrhythmia
 - Idiopathic (cause unknown)

Commonly Dilated: Large, Weak, Heart

- Refractory volume overload
- Hypotension
- Decreased renal function
- 🗕 Hyponatremia
- Elevated serum natriuretic peptide

CXR

- Exercise testing (6minute walk in those that can ambulate)
- Echo
- Right heart cath



NYHA Class Level of Clinical Impairment



No limitation of physical activity. Ordinary physical activity does not cause undue breathlessness, fatigue, or palpitations.



Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in undue breathlessness, fatigue, or palpitations.



Marked limitation of physical activity. Comfortable at rest, but less than ordinary physical activity results in undue breathlessness, fatigue, or palpitations.



Unable to carry on any physical activity without discomfort. Symptoms at rest can be present. If any physical activity is undertaken, discomfort is increased.

Creative commons image



- Stage A → At risk for HF but no structural disease or symptoms
- Stage B → Structural disease but no signs or symptoms. This stage includes patients in NYHA class I without current symptoms or signs of HF.
- Stage C → Structural disease with prior or current symptoms. This stage includes patients in any NYHA class.
- Stage D → Refractory HF requiring specialized interventions. This stage includes patents in NYHA class IV with refractory HF.

At Risk for Heart Failure

Structural

heart

disease

STAGE A At high risk for HF but without structural heart disease or symptoms of HF

eq, PATIENTS WITH:

hypertension

- atherosclerotic disease
- diabetes
- obesity metabolic syndrome

or PATIENTS

using cardiotoxins with FHx CM

THERAPY GOALS

- Treat hypertension
- Encourage smoking cessation
- Treat lipid disorders
- Encourage regular exercise
- Discourage alcohol intake, illicit drug use
- **Control metabolic** syndrome

DRUGS

ACEI or ARB in appropriate patients (see text) for vascular disease or diabetes

STAGE B Structural heart disease but without signs or symptoms of HF

eg, PATIENTS WITH: previous MI LV remodeling Development of symptoms including LVH and of HF

THERAPY GOALS

- All measures under stage A

DRUGS

- ACEI or ARB in appropriate patients (see text)
- Beta-blockers in appropriate patients
- (see text)

low EF

asymptomatic

valvular disease

Heart Failure

Refractory

symptoms of

HF at rest

STAGE C Structural heart disease with prior or current symptoms of HF

eg, PATIENTS WITH: known structural heart disease and shortness of breath and fatigue, reduced exercise tolerance

THERAPY

GOALS - All measures under stages A and B

- Dietary salt restriction

DRUGS FOR ROUTINE USE

- Diuretics for fluid retention
- ACEI
- Beta-blockers

DRUGS IN SELECTED PATIENTS

- Aldosterone antagonist
- ARBs
- Digitalis
- Hydralazine/nitrates

DEVICES IN SELECTED PATIENTS

- Biventricular pacing
- Implantable defibrillators

STAGE D **Refractory HF** requiring specialized interventions

eq. PATIENTS

who have marked symptoms at rest despite maximal medical therapy (eg, those who are recurrently hospitalized or cannot be safety discharged from the hospital without specialized interventions)

THERAPY

- GOALS
- Appropriate measures under stages A, B, C
- **Decision re: appropriate** level of care

OPTIONS

- Compassionate end-oflife care/hospice
- Extraordinary measures
 - heart transplant
 - chronic inotropes
 - permanent mechanical support
 - experimental surgery or drugs

ACC/AHA Heart Failure Guidelines

Goals of treatment

- HFrEF improve symptoms, slow or reverse deterioration in myocardial function, reduce mortality
- Diuretics; Loop (Fureosemide, Bumetanide or Torsemide)
- Beta blockers (Carvedilol, Metoprolol, Bisoprolol)
- ACE inhibitors (Lisinopril, Enalapril or Quinapril), ARBs or Angiotensin receptor-neprilysin inhibitors (Sacubitril-Valsartan) (ARNI)
- Hydralazine plus nitrate (isosorbide dinitrate)
- Digoxin
- Aldosterone Receptor Antagonists (Spironolactone or Epleronone)

Divide the Divide t for all ARNI or ACE? ARNI* may be initiated in any NYHA class II or III patients with LVEF ≥40 BB with proven benefit of reduced all cause mortality recommended for all

Hydralazine plus oral nitrate:

- When pt. cannot tolerate ACE/ARNI/ARB
- In black patients with class III HF and LVEF <40 despite optimal therapy</p>
- Ivabradine for patients with LVEF of ≤35% with a HR of at least 70bpm at rest, optimized on BB therapy
- Algosterone receptor antagonist for:
 - Patients with NYHA class II HF and LVEF ≤30 or NYHA class III or IV and LVEF ≤35
 - Post STEMI patients already receiving therapeutic doses of ACEI with LVEF ≤40 and either symptomatic HF, or DM

Digoxin should be reserved for patients who continue to have NYHA class III and IV despite optimal therapy and/or a LVEF of 25 or less

► HFpEF → treatment is largely directed toward associated conditions and symptoms

- Still not a lot of good evidence in this group of HF patients regarding treatment!
- ► HTN managing systemic blood pressure is a key component → prevention of morbidity
 - Divide the provide the symptoms due to volume overload
 - Aldosterone receptor antagonist may have a role monitoring is important

- HFpEF treatment is largely directed toward associated conditions
 - Treat contributing factors (HTN, lung dz, CAD, obesity, anemia, DM, Kidney dz)
 - Diuretics, control HR (esp. in a-fib) prefer restoration and maintenance of sinus if possible otherwise rate control
 - Don't use BB unless there is another indication like angina
 - Nitrates in pts with LV diastolic dysfunction (small and stiff) leading to underfilling → fall in cardiac output, hypotension. (they are susceptible to preload reduction)
 - Similar morbidity as patients with HFrEF

Drug therapy for Heart Failure - Compensated

- Here are a list of Drugs and classes that may help:
 - Beta blocker
 - 2. Ace inhibitor/Angiotensin receptor blocker
 - Angiotensin blocker and Neprilysin inhibitor
 - 3. Aldosterone receptor antagnoists (spironolactone, eplerenone)
 - 4. Diuretic
 - Hydralazine + Nitrate
 - Digoxin
- Which improve survival?
- Which improve symptoms only (feel better, less hospital stays)?

Cardiac Rehabilitation

- Indicated for both types of HF
 - Approved for payment by all payers (Medicare, Medicaid and third party
- A 2016 study of >14,000 patients in 2016 showed (various cardiovascular conditions)
 - A lower risk of cardiovascular death (relative risk [RR] 0.74, 95% CI 0.64-0.86)
 - A lower risk of hospital admission (RR 0.82, 95% CI 0.70-0.96)
- Despite this utilization rates are low
 - ?referral rates

Acute Heart Failure

■ Acute decompensated heart failure (ADHF) → a clinical syndrome of new or worsening HF signs and symptoms that often lead to hospitalization or a visit to the Emergency Department. (high post discharge readmit rates)

Can result from HFpEF or HFrEF

Diagnosis is clinical; can be supported with test results but should not be made based off a single test

Admission to the hospital is common



How do you get from Acute to Chronic CHF?

Chronic HF – Compensated

 Still have underlying cardiac problem but meds, rehab, diet

 \rightarrow reduced symptoms

Sympathetic Nervous System – Epi & Norepi – Blocked by Beta Blocker

HR decreases

<u>Renin-Angiotensin – Aldosterone</u> – Blocked by Ace – inhibitor, Angiotensin receptor blocker, Aldosterone receptor antagonist (spironolactone)

Reduces vasoconstriction, fluid and sodium retention

Antidiuretic Hormone- Reversed by diuretic

Precipitants of heart failure

Dietary indiscretion	
Vigorous fluid administration	
Noncompliance to medical regimen	
Worsening renal failure	
Uncontrolled hypertension	
Anemia	
Systemic infection	
Pulmonary embolism	
Myocardial ischemia	
Tachyarrhythmias and bradyarrhythmias	
Electrolyte disturbances	
Severe emotional or physical stress	
Hyperthyroidism and hypothyroidism	
Cardiodepressant and other drugs	
Anti-inflammatory drugs	
Antiarrhythmic drugs	
Calcium channel blockers	
Beta adrenergic blocking agents	
	UpToDate®

Common presentation - ADHF

Acute dyspnea, orthopnea, tachypnea, tachycardia, HTN

Hypotension in severe disease

Accessory muscle use

Diffuse pulmonary crackles, possible wheezing

Elevated JVD, peripheral edema, an S3



BNP – Brain Natriuretic Peptide

Breathing Near ImPossible

BNP – Brain Natriuretic Peptide Also Pro BNP or NT-Pro BNP

BNP

- Released from ventricles
- Role is to counteract the renin-angiotensin system, endothelin, and sympathetic system
- Shown to be better than clinical assessment
- <100pg/ml very high negative predictive value</p>
- >400pg/ml in dyspneic patient very likely HF
- Has been shown to predict mortality and degree of decompensation

Acute decompensated HF: Management

Treat any underlying cause

- Possible: ACS, Acute HTN, Worsening Valve, Arrhythmia, etc.
- Treat hypoxia assisted ventilation if needed

Diuresis

- Consider afterload reduction (Vasodilation)
- If known HFrEF and appear to be in cardiogenic shock → discontinue
 BB therapy, Give IV inotrope and/or mechanical support

If known HFpEF and appear to be in cardiogenic shock \rightarrow IV fluid (unless pulmonary edema present) and give IV vasopressor (Do not give inotrope) If outflow obstruction is suspected BB may be indicated If unknown \rightarrow Give inotrope with or without vasopressor, assess for mechanical support

If I can't tell if patient has HFpEF or HFrEF from exam & history...

Echocardiogram

- Computer measures volume before and after systole and calculates an EF%
- Valves: You can measure Stenosis, Regurgitation
- Can tell you where the LV is damaged:
 - HTN, DM, viruses, drugs tend to cause all over damage to the LV
 - A blocked artery tends to cause a region of the LV to not move so well.



Medical Management of Advanced Heart Failure



 Safest place to be is Warm and Dry

- Good Perfusion no congestion
- Worst for patient is Cold and Wet
 - Poor perfusion and + congestion
 - Cardiogenic Shock
 - Needs a Pressor and a diuretic potentially

Nohria A, et al. JAMA 2006;287:628-640.

Pharmacotherapy for Heart Failure: Summary

Acute HF

Chronic HF

- Focus on restoration of normal perfusion and relief of congestion.
- Need drugs that work fast & reduce symptoms.
 - Diuretics Loop (furosemide) for Wet
 - Pressors/Inotropes (Dopamine, Dobutamine, others) For Cold (perfusion)
 - Change high dose IV meds for acute failure, to doses that are oral and lower potency when ready for discharge

- Focus on maintenance of fluid, electrolyte status & hormone blocking
- Drugs that reduce morbidity & mortality
 - Beta Blocker
 - ACE inhibitor, ARB, ARNI
 - Aldosterone antagonists if EF below 35%

40

Treatment: General approach to managing CHF -Improve the underlying condition

HTN
Ischemia
Valve disease
Renal Failure
Arrhythmia
Anemia
Sleep apnea

► PE

41

These can be the root cause of initial CHF episode or be a chronic contributor to worsening

Heart Failure - Natural History

6 mil Americans, 3% of general population, 20% of elderly

- \$40 Billion in annual health care costs
- Survival: Average 16 months from first hospitalization

NYHA CHF Class	1 yr Mortality
I - Mild	5-10%
II-III - Moderate	15-30%
IV - Severe	50-60%

Which has better prognosis? HFpEF or HFrEF?



Off all cases of HF about 34% are HFpEF and 66% are HFrEF

Planning in CHF is difficult

Patients w/ condition who have a Do not resuscitate (DNR) order:

- 5% in CHF
- ► 47% in Cancer
- Only 4% of patients dying of HF get palliative care
 - 40% in cancer

Prognostication in Heart Failure

- Markers of poor prognosis
 (< 6 months expected survival)
 - Low Sodium
 - Liver failure, renal failure, delirium
 - Unable to tolerate meds due to low BP
 - Symptoms at rest
 - Frequent hospitalizations
 - Cachexia
 - Lymphopenia



When to get Cardiology or Cardiac Surgeon involved?

Referrals for Advanced Heart Failure: Dos and Don'ts

• Do:

- Discuss and consider advanced HF therapies when class III
 - Hyponatremia (NA <136)
 - BUN >45, Crea >2.5
 - BNP >4x upper normal limit
 - Diuretic dose >2.0 mg/kg/dl
 - Inability to take ACE/ARB/BB
- Consider if frequent arrhythmia

• Don't:

- Wait for progressive renal dysfunction
- Wait for multiple pressors
- Wait for cardiac cachexia

Successful Treatment of Congestive Heart Failure = Complex Multidisciplinary Management Strategy



CHF symptoms at end of life: Ask/ address/ palliate symptoms even if heart function can't be improved.



In HFpEF treatment should be aimed at associated conditions

Diuretics, (ACEI, ARB, ARNI), BB for all patients with HFrEF

ACEI, ARB, ARNI, BB, Hydralyzine + Nitrate (in those that need it) improve survival

Consider multidisciplinary management strategy for treatment of HF patients



Thank you!

50